Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.

Source:http://linkedlifedata.com/resource/pubmed/id/11459659

Bioorg. Med. Chem. Lett. 2001 Jul 23 11 14 1911-4

Download in:

View as

Triples

General Info

PMID
11459659